Effectiveness of Donor Natural Killer Cell Alloreactivity in Mismatched Hematopoietic Transplants
The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
T cells that accompany allogeneic hematopoietic grafts for treating leukemia enhance engraftment and mediate the graft-versus-leukemia effect. Unfortunately, alloreactive T cells also cause graft-versus-host disease (GVHD). T cell depletion prevents GVHD but increases the risk of graft rejection and leukemic relapse. In human transplants, we show that donor-versus-recipient natural killer (NK)-cell alloreactivity could eliminate leukemia relapse and graft rejection and protect patients against GVHD. In mice, the pretransplant infusion of alloreactive NK cells obviated the need for high-intensity conditioning and reduced GVHD. NK cell alloreactivity may thus provide a powerful tool for enhancing the efficacy and safety of allogeneic hematopoietic transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“NK cells, which act as important immune cells, are widely used for transplantation [82,83].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [82]
Citations
Cites
Selective rejection of H–2-deficient lymphoma variants suggests alternative immune defence strategy
Kärre, K., Ljunggren, H. G., Piontek, G., & Kiessling, R. (1986) · Nature · doi:10.1038/319675a0 · Cited by 2,161
Lanier, L. L. (1998) · Annual Review of Immunology · doi:10.1146/annurev.immunol.16.1.359 · Cited by 1,648
Prevention of Graft Versus Host Disease by Inactivation of Host Antigen-Presenting Cells
Shlomchik, W. D., Couzens, M. S., Tang, C. B., McNiff, J., Robert, M. E., Liu, J., Shlomchik, M. J., & Emerson, S. G. (1999) · Science · doi:10.1126/science.285.5426.412 · Cited by 1,186
Self-citationAversa, F., Tabilio, A., Velardi, A., Cunningham, I., Terenzi, A., Falzetti, F., Ruggeri, L., Barbabietola, G., Aristei, C., Latini, P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810223391702 · Cited by 1,168
Self-citationRole of Natural Killer Cell Alloreactivity in HLA-Mismatched Hematopoietic Stem Cell Transplantation
Ruggeri, L., Capanni, M., Casucci, M., Volpi, I., Tosti, A., Perruccio, K., Urbani, E., Negrin, R. S., Martelli, M. F., & Velardi, A. (1999) · Blood · doi:10.1182/blood.v94.1.333.413a31_333_339 · Cited by 994
Self-citationHematopoietic Cell Transplantation
Forman, S. J., & Nakamura, R. (2015) · Blackwell Science Ltd eBooks · Cited by 659
Aversa, F., Tabilio, A., Terenzi, A., Velardi, A., Falzetti, F., Giannoni, C., Iacucci, R., Zei, T., Martelli, M., & Gambelunghe, C. (1994) · Blood · doi:10.1182/blood.v84.11.3948.bloodjournal84113948 · Cited by 576
Self-citationColonna, M., Borsellino, G., Falco, M., Ferrara, G. B., & Strominger, J. L. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.12000 · Cited by 460
Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice
Bachar-Lustig, E., Rachamim, N., Li, H.-W., Lan, F., & Reisner, Y. (1995) · Nature Medicine · doi:10.1038/nm1295-1268 · Cited by 322
Generation of Allospecific Natural Killer Cells by Stimulation Across a Polymorphism of HLA-C
Colonna, M., Brooks, E. G., Falco, M., Ferrara, G. B., & Strominger, J. L. (1993) · Science · doi:10.1126/science.8493555 · Cited by 234
Research works printed but not linked: 3
- Valiante N. M., Parham P., Biol. Blood Marrow Transplant. 3, 229 (1997).
- A supplementary table and experimental procedures are available on Science Online at www.sciencemag.org/cgi/content/full/295/5562/2097/DC1.
- We thank A. Santucci for statistical analyses L. Romani for critical review of the manuscript and G. Boyd for her essential role in manuscript editing. Supported by grants from the Italian Association for Cancer Research the Italian Ministry of Research and the Italian Ministry of Health and by a translational research grant from the Leukemia and Lymphoma Society. W.D.S. is supported by NIH grant number HL03979.
Cited by
Items 801–900 of 1,002
Novel insights in CAR-NK cells beyond CAR-T cell technology; promising advantages
Ebrahimiyan, H., Tamimi, A., Shokoohian, B., Minaei, N., Memarnejadian, A., Hossein‐Khannazer, N., Hassan, M., & Vosough, M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108587 · Cited by 69
Haroun-Izquierdo, A., Vincenti, M., Netskar, H., van Ooijen, H., Zhang, B., Bendzick, L. E., Kanaya, M., Momayyezi, P., Li, S., Wiiger, M. T., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005577 · Cited by 67
“8 Therefore, it was postulated that NK cells might be particularly effective when transferred across HLA barriers, 9 10 where NK cell alloreactivity would be unleashed through mismatch between donor NK clones bearing inhibitory killer immunoglobulin-like receptor (KIR) specific for self-HLA class I…”
Flaadt, T., Ladenstein, R. L., Ebinger, M., Lode, H. N., Arnardóttir, H. B., Pöetschger, U., Schwinger, W., Meisel, R., Schuster, F. R., Döring, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01630 · Cited by 64
“censored): 5 years 5 years 9 (0) 8 (0) 8 (0) 8 (0) 6 (2) 5 (3) 4 (4) 4 (4) 2 (6) 1 (7) 59 47 (0) 34 (2) 29 (3) 26 (5) 23 (8) 19 (10) 15 (14) 13 (16) 6 (23) 4 (25) 5 years ≥ 5 years Log-rank P = .”
InfluentialUnderstanding NK cell biology for harnessing NK cell therapies: targeting cancer and beyond
Shin, E., Bak, S. H., Park, T., Kim, J.-W., Yoon, S. R., Jung, H., & Noh, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1192907 · Cited by 79
“Researchers have found that HLA haplotype-mismatched grafts with KIR ligand incompatibility can greatly reduce relapse in posttransplant acute myeloid leukemia (AML) (74).”
BackgroundIL-7 Enhances Survival of Human CD56bright NK Cells
Michaud, A., Dardari, R., Charrier, E., Cordeiro, P., Herblot, S., & Duval, M. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181cd872d · Cited by 73
“NK cell activation after stem cell transplantation in humans was shown to improve the incidence of favorable outcome.(4,5) Our findings, however, show that IL-7 does not activate NK cells although it enhances the survival of the noncytotoxic CD56 NK subset.”
BackgroundOptimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A
Sarkar, S., van Gelder, M., Noort, W. A., Xu, Y., Rouschop, K. M. A., Groen, R. W. J., Schouten, H. C., Tilanus, M. G. J., Germeraad, W. T. V., Martens, A. C., et al. (2015) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-015-1694-4 · Cited by 69
“Landmark studies in the haplo-identical HSCT setting showed that KIR–ligand-mismatched NK cells exert anti-leukemic effects and improve survival of acute myeloid leukemia (AML) patients [14, 15].”
BackgroundDendritic Cell Interactions with NK Cells from Different Tissues
Ferlazzo, G., & Münz, C. (2009) · Journal of Clinical Immunology · doi:10.1007/s10875-009-9283-y · Cited by 68
“This cytolytic DC editing by NK cells has been suggested to reduce graftversus-host disease in bone marrow transplantation [86] and graft rejection in solid organ transplantation [87, 88].”
BackgroundMicro RNA function in NK‐cell biology
Beaulieu, A. M., Bezman, N. A., Lee, J. E., Matloubian, M., Sun, J. C., & Lanier, L. L. (2013) · Immunological Reviews · doi:10.1111/imr.12045 · Cited by 62
Kearney, C. J., Ramsbottom, K. M., Voskoboinik, I., Darcy, P. K., & Oliaro, J. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1196308 · Cited by 70
“Indeed, T-cell depletion increases the incidence of relapse after ASCT, but does alleviate GVHD.(5) Furthermore, poor cytotoxic NK cell activity may be restored through generation of KIRdependent allo-reactivity, and through re-expression of NKcell-activating receptors such as DNAM-1 and NKG2D.”
BackgroundBertaina, A., Zorzoli, A., Petretto, A., Barbarito, G., Inglese, E., Merli, P., Lavarello, C., Brescia, L. P., Angelis, B. D., Tripodi, G., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1216291 · Cited by 66
“Human gd T cells orchestrate cellular activities of both innate and adaptive immunity7-11 and, unlike ab T lymphocytes, recognize tumors in a MHC-independent manner and do not cause GvHD.7,11 These lymphocytes elicit antitumor responses, and have clinical appeal based on their cytotoxicity toward tumor cells and on th…”
BackgroundInfluentialMancusi, A., Ruggeri, L., & Velardi, A. (2016) · Blood · doi:10.1182/blood-2016-07-730564 · Cited by 69
“Transplantation from NK alloreactive donors reduced AML relapse but not ALL relapse (as previously demonstrated in the standard T cell–depleted haploidentical protocol).(18-22,93,94) 2618 MANCUSI et al BLOOD, 8 DECEMBER 2016 x VOLUME 128, NUMBER 23 For personal use only.”
BackgroundResultInfluentialSelf-citationHeinze, A., Grebe, B., Bremm, M., Huenecke, S., Munir, T., Graafen, L., Frueh, J. T., Merker, M., Rettinger, E., Soerensen, J., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02816 · Cited by 62
“The beneficial GvL/T effect is predominantly mediated by NK cells that are key players of the innate immune system and potent effector cells participating in the defense of viralinfected and malignant cells (10).”
BackgroundTaveirne, S., Wahlen, S., Loocke, W. V., Kiekens, L., Persyn, E., Ammel, E. V., Mulder, K. D., Roels, J., Tilleman, L., Aumercier, M., et al. (2020) · Blood · doi:10.1182/blood.2020005204 · Cited by 81
Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study
Lewalle, P., Triffet, A., Delforge, A., Crombez, P., Selleslag, D., Muynck, H. D., Bron, D., & Martiat, P. (2003) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1703779 · Cited by 64
Hematopoietic Cell Transplantation for Benign Hematological Disorders and Solid Tumors
Storb, R. F., Lucarelli, G., McSweeney, P. A., & Childs, R. W. (2003) · Hematology · doi:10.1182/asheducation-2003.1.372 · Cited by 64
Challenges and Recent Advances in NK Cell-Targeted Immunotherapies in Solid Tumors
Lian, G., Mak, T. S., Yu, X., & Lan, H. Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010164 · Cited by 72
Balanced engagement of activating and inhibitory receptors mitigates human NK cell exhaustion
Myers, J. A., Schirm, D. K., Bendzick, L. E., Hopps, R., Selleck, C., Hinderlie, P., Felices, M., & Miller, J. S. (2022) · JCI Insight · doi:10.1172/jci.insight.150079 · Cited by 63
“especially hematologic malignancies (1, 2).”
Kopp, L. M., Ray, A., Denman, C. J., Senyukov, V., Somanchi, S. S., Zhu, S., & Lee, D. A. (2013) · Molecular Immunology · doi:10.1016/j.molimm.2012.12.012 · Cited by 63
Kanda, Y., Oshima, K., Asano‐Mori, Y., Kandabashi, K., Nakagawa, M. M., Sakata‐Yanagimoto, M., Izutsu, K., Hangaishi, A., Tsujino, S., Ogawa, S., et al. (2005) · Transplantation · doi:10.1097/01.tp.0000158718.49286.14 · Cited by 63
“A possible disadvantage of alemtuzumab is that alemtuzumab may kill NK cells, which may be important for a graft-versus-leukemia/lymphoma effect (29).”
BackgroundClave, E., Lisini, D., Douay, C., Giorgiani, G., Busson, M., Zecca, M., Moretta, F., Acquafredda, G., Brescia, L. P., Locatelli, F., et al. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00054 · Cited by 64
“ORIGINAL RESEARCH ARTICLE published: 04 March 2013 doi: 10.3389/fimmu.2013.00054 Thymic function recovery after unrelated donor cord blood or T-cell depleted HLA-haploidentical stem cell transplantation correlates with leukemia relapse”
BackgroundMethodInfluentialFedermann, B., Haegele, M., Pfeiffer, M. M., Wirths, S., Schumm, M., Faul, C., Vogel, W., Handgretinger, R., Kanz, L., & Bethge, W. A. (2010) · Leukemia · doi:10.1038/leu.2010.235 · Cited by 63
Clinical Relevance of Natural Killer Cells Following Hematopoietic Stem Cell Transplantation
Palmer, J. M., Rajasekaran, K., Thakar, M. S., & Malarkannan, S. (2013) · Journal of Cancer · doi:10.7150/jca.5049 · Cited by 65
Pittari, G., Liu, X.-R., Selvakumar, A., Zhao, Z.-G., Merino, E., Huse, M., Chewning, J., Hsu, K. C., & Dupont, B. (2013) · Journal of Immunology · doi:10.4049/jimmunol.1202120 · Cited by 60
“Allogeneic NK cells also participate in protecting HCT recipients against leukemia relapse, and this effect is primarily observed in patients with acute myeloid leukemia (AML).”
BackgroundInfluentialBozward, A. G., Warricker, F., Oo, Y. H., & Khakoo, S. I. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.643310 · Cited by 68
“It has been shown that NKcell alloreactivity can eliminate the risk of leukaemia relapse and graft rejection as well as protecting against graft-versus-host disease in transplant patients (112).”
BackgroundZeiser, R., Marks, R., Bertz, H., & Finke, J. (2004) · Annals of Hematology · doi:10.1007/s00277-004-0890-7 · Cited by 69
“Conversely, the observation that alloreactive NK cells exert cytotoxicity on recipient lymphocytes, myeloid cells, and APCs suggests that donor NK cells may even reduce GVHD while preserving the graft-versus-leukemia (GVL) effect [21].”
BackgroundResultInfluentialBone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD)
Blazar, B. R., & Murphy, W. J. (2005) · Philosophical Transactions of the Royal Society B Biological Sciences · doi:10.1098/rstb.2005.1701 · Cited by 70
Mikelez-Alonso, I., Magadán, S., González‐Fernández, Á., & Borrego, F. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113860 · Cited by 64
Engineering innate immune cells for cancer immunotherapy
Tarannum, M., Ding, X., Barisa, M., Hu, S., Anderson, J., Romee, R., & Zhang, J. (2025) · Nature Biotechnology · doi:10.1038/s41587-025-02629-5 · Cited by 65
“An early study highlighted the role of donor NK cells in mediating graft-versus-leukemia effects in high-risk individuals with AML undergoing haploidentical hematopoietic stem cell transplant, sparking considerable interest in NK cell-based therapies 87 .”
Positive and Negative Regulation by NK Cells in Cancer
Sungur, C. M., & Murphy, W. J. (2014) · Critical Reviews™ in Oncogenesis · doi:10.1615/critrevoncog.2014010805 · Cited by 71
Alemtuzumab for the prevention and treatment of graft-versus-host disease
Kanda, J., Lopez, R. D., & Rizzieri, D. A. (2011) · International Journal of Hematology · doi:10.1007/s12185-011-0802-2 · Cited by 66
Yabe, T., Matsuo, K., Hirayasu, K., Kashiwase, K., Kawamura-Ishii, S., Tanaka, H., Ogawa, A., Takanashi, M., Satake, M., Nakajima, K., et al. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2007.09.012 · Cited by 62
Xing, D., Ramsay, A. G., Gribben, J. G., Decker, W. K., Burks, J. K., Munsell, M., Li, S., Robinson, S. N., Yang, H. Y., Steiner, D., et al. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181e475e9 · Cited by 69
“BASIC STUDY 684 | www.immunotherapy-journal.com J Immunother Volume 33, Number 7, September 2010 reduce the NK antitumor response.13,14 Thus, understanding the cellular mechanism of suppressed cytolytic CB-NK cell activity and identifying exvivo expansion strategies should facilitate the use of activated CB-NK cells f…”
BackgroundResultInfluentialThe innate natural killer cells in transplant rejection and tolerance induction
Kroemer, A., Edtinger, K., & Li, X. C. (2008) · Current Opinion in Organ Transplantation · doi:10.1097/mot.0b013e3283061115 · Cited by 62
Ogawa, H., Ikegame, K., Kaida, K., Yoshihara, S., Fujioka, T., Taniguchi, Y., Tamaki, H., Inoue, T., Hasei, H., Iiboshi, Y., et al. (2007) · Experimental Hematology · doi:10.1016/j.exphem.2007.08.013 · Cited by 62
Hematopoietic stem cell transplantation in sickle cell disease
Vermylen, C. (2003) · Blood Reviews · doi:10.1016/s0268-960x(03)00006-7 · Cited by 62
Gur, H., Krauthgamer, R., Bachar-Lustig, E., Katchman, H., Arbel‐Goren, R., Berrébi, A., Klein, T., Nagler, A., Tabilio, A., Martelli, M. F., et al. (2004) · Blood · doi:10.1182/blood-2002-11-3463 · Cited by 63
Self-citationSekine, T., Marin, D., Cao, K., Li, L., Mehta, P., Shaim, H., Sobieski, C. E., Jones, R. B., Oran, B., Hosing, C., et al. (2016) · Blood · doi:10.1182/blood-2016-03-706317 · Cited by 61
“Finally, we did not observe any beneficial effect of KIR-ligand mismatch (data not shown), as reported in early studies post-HSCT.(1,28) These observations emphasize the importance of the combination of NK licensing and activating KIRs, as opposed to only KIR-ligand mismatch or the presence of an activatingKIRper se,…”
BackgroundResultLeveque, L., Koyama, M., Texier, L. L., Markey, K. A., Cheong, M., Kuns, R. D., Lineburg, K. E., Teal, B. E., Alexander, K. A., Clouston, A. D., et al. (2016) · Blood · doi:10.1182/blood-2015-11-680876 · Cited by 63
“The curative property of BMT lies mainly the immune-mediated graft-versusleukemia effect, which eradicates residual recipient leukemia by T and natural killer (NK) cells.(1,2) The wider application of this treatment is limited by serious posttransplantation complications, including graftversus-host disease (GVHD).”
BackgroundProphylaxis and Treatment of Acute Graft-Versus-Host Disease
Chao, N. J. A., & Chen, B. J. (2006) · Seminars in Hematology · doi:10.1053/j.seminhematol.2005.09.007 · Cited by 64
Koehl, U., Bochennek, K., Zimmermann, S. Y., Lehrnbecher, T., Sörensen, J., Esser, R., Andreas, C., Kramm, C. M., Grüttner, H. P., Falkenberg, E., et al. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705584 · Cited by 62
KIR Gene in Ethnic and Mestizo Populations from Mexico
Gutiérrez‐Rodríguez, M., Sandoval-Ramírez, L., Díaz-Flores, M., Marsh, S. G. E., Valladares‐Salgado, A., Madrigal, J. A., Mejía‐Aranguré, J. M., García-Sepúlveda, C. A., Huerta‐Zepeda, A., Ibarra‐Cortés, B., et al. (2006) · Human Immunology · doi:10.1016/j.humimm.2005.11.007 · Cited by 68
Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy
Zhou, Y., Li, M., Zhou, K., Brown, J., Tsao, T., Cen, X., Husman, T., Bajpai, A., Dunn, Z. S., & Yang, L. (2022) · Cancers · doi:10.3390/cancers14092266 · Cited by 64
BSHI guideline: HLA matching and donor selection for haematopoietic progenitor cell transplantation
Little, A., Akbarzad‐Yousefi, A., Anand, A., Burlinson, N. D., Dunn, P. P. J., Evseeva, I., Latham, K., Poulton, K., Railton, D., Vivers, S., et al. (2021) · International Journal of Immunogenetics · doi:10.1111/iji.12527 · Cited by 71
Adaptive NK cell response to human cytomegalovirus: Facts and open issues.
López-Botet, M., de Maria, A., Muntasell, A., Chiesa, M. D., & Vilches, C. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101706 · Cited by 58
Siegler, U., Kalberer, C. P., Nowbakht, P., Sendelov, S., Meyer‐Monard, S., & Wodnar-Filipowicz, A. (2005) · Leukemia · doi:10.1038/sj.leu.2403985 · Cited by 70
Mapping MHC haplotype effects in unrelated donor hematopoietic cell transplantation
Petersdorf, E. W., Malkki, M., Horowitz, M. M., Spellman, S. R., Haagenson, M. D., & Wang, T. (2013) · Blood · doi:10.1182/blood-2012-11-465161 · Cited by 61
Unmanipulated HLA-Mismatched/Haploidentical Blood and Marrow Hematopoietic Stem Cell Transplantation
Huang, X., & Chang, Y. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.03.006 · Cited by 61
“In contrast to other authors’ reports [53,54], we found that the 3-year probability of relapse was 24.”
ResultAdoptive T cell therapy: Addressing challenges in cancer immunotherapy
Yee, C. (2005) · Journal of Translational Medicine · doi:10.1186/1479-5876-3-17 · Cited by 61
“Although this discussion is limited to the treatment of solid tumor malignancies, it should be noted that the adoptive transfer of allogeneic effector cells including donor lymphocyte infusions [12], minor antigen-specific CTL [13] and strategies that exploit NK alloreactivity [14] have been used successfully for the…”
Espinoza, J. L., Takami, A., Onizuka, M., Sao, H., Akiyama, H., Miyamura, K., OKAMOTO, S., Inoue, M., Kanda, Y., Ohtake, S., et al. (2009) · Haematologica · doi:10.3324/haematol.2009.008318 · Cited by 64
“Alloreactive NK cells reduced the risk of relapse of acute myeloid leukemia without increasing the incidence of GVHD, resulting in a marked improvement of event-free survival in a series of haploidentical transplant recipients.(35,36) In HLA-identical sibling transplants, the absence of HLA-C and HLA-B ligand for dono…”
BackgroundMechanisms of Resistance to NK Cell Immunotherapy
Sordo‐Bahamonde, C., Vitale, M., Lorenzo‐Herrero, S., López‐Soto, A., & Gonzalez, S. R. (2020) · Cancers · doi:10.3390/cancers12040893 · Cited by 70
“Patients with AML lacking KIR ligands in T cell-depleted haploidentical donors exhibited a reduced risk of leukemia relapse and GvHD, as well as increased overall survival [54,55].”
BackgroundImmunotherapy-Based Targeting and Elimination of Leukemic Stem Cells in AML and CML
Valent, P., Sadovnik, I., Eisenwort, G., Bauer, K., Herrmann, H., Gleixner, K. V., Schulenburg, A., Rabitsch, W., Sperr, W. R., & Wolf, D. G. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174233 · Cited by 66
Cany, J., van der Waart, A. B., Spanholtz, J., Tordoir, M., Jansen, J. H., van der Voort, R., Schaap, N. P., & Dolstra, H. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1017701 · Cited by 66
“Importantly, prolonged relapse-free survival has been demonstrated in allotransplanted AML patients in the setting of killer immunoglobulin-like receptor (KIR)-ligand mismatch between patients and allogeneic donors.(5-7) In this situation, AML cells of the patient lack an inhibitory HLA ligand for the allogeneic donor…”
BackgroundNatural killer cell activation by dendritic cells: balancing inhibitory and activating signals
da Silva, R. B., & Münz, C. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0801-8 · Cited by 60
“Moreover, DC killing by NK cells can also be harnessed clinically to remove allogeneic DCs that could elicit graft-versus-host disease during bone marrow transplantation, or allograft rejection [159, 160].”
BackgroundMiddleton, D., Diler, A. S., Meenagh, A., Sleator, C., & Gourraud, P. (2009) · Tissue Antigens · doi:10.1111/j.1399-0039.2009.01235.x · Cited by 60
Vago, L., Toffalori, C., Ciceri, F., & Fleischhauer, K. (2012) · Seminars in Oncology · doi:10.1053/j.seminoncol.2012.09.009 · Cited by 60
Dunbar, E. M., Buzzeo, M. P., Levine, J. B., Schold, J. D., Meier-Kriesche, H.-U., & Reddy, V. S. (2008) · Haematologica · doi:10.3324/haematol.13033 · Cited by 64
“The primary outcomes chosen for analysis were relapse, death, and acute GVHD.”
BackgroundInfluentialHLA mismatching as a strategy to reduce relapse after alternative donor transplantation
Fleischhauer, K., & Beelen, D. W. (2016) · Seminars in Hematology · doi:10.1053/j.seminhematol.2016.01.010 · Cited by 63
“Haploidentical transplantation is particularly attractive for GvL, due to the large number of alloreactive T-cell targets encoded by the fully mismatched haplotype (Table 1), as well as the strong effect of NK cell alloreactivity to missing self HLA-C and -B suggested by the early studies in T-cell–deplete settings [6…”
BackgroundPD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells
Guo, Y., Feng, X., Jiang, Y. Z., Shi, X., Xing, X., Liu, X., Li, N., Fadeel, B., & Zheng, C. (2016) · Oncotarget · doi:10.18632/oncotarget.10235 · Cited by 64
de Koning, C. C. H., Nierkens, S., & Boelens, J. J. (2016) · Blood · doi:10.1182/blood-2016-06-724005 · Cited by 63
Wagner, J. A., Berrien-Elliott, M. M., Rosario, M., Leong, J. W., Jewell, B. A., Schappe, T., Abdel-Latif, S., & Fehniger, T. A. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.11.018 · Cited by 64
Nakamura, T., Yamada, K., Fujiwara, Y., Sato, Y., & Harashima, H. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b01166 · Cited by 61
Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer
Patel, S., Burga, R. A., Powell, A. B., Chorvinsky, E. A., Hoq, N., McCormack, S., Pelt, S. N. V., Hanley, P. J., & Cruz, C. C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00196 · Cited by 62
Gao, F., Ye, Y., Gao, Y., Huang, H., & Zhao, Y. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.02022 · Cited by 63
“In HLA-mismatched transplants, the Perugia group first observed that, in the context of T cell depletion, high stem cell dose, and absence of post-transplant immune suppression, KIR ligand mismatch reduced the risk of relapse and markedly improved survival in patients with AML, but not in those with acute lymphoblast…”
BackgroundResultInfluentialMatthes‐Martin, S., Lion, T., Haas, O. A., Frommlet, F., Daxberger, H., König, M., Printz, D., Scharner, D., Eichstill, C., Peters, C., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403087 · Cited by 60
KIR/HLA Ligand Incompatibility in Kidney Transplantation
Kunert, K., Seiler, M., Mashreghi, M., Klippert, K., Schönemann, C., Neumann, K., Pratschke, J., Reinke, P., Volk, H., & Kotsch, K. (2007) · Transplantation · doi:10.1097/01.tp.0000290681.41859.41 · Cited by 68
“(20) first illustrated that KIR ligand incompatibility (or HLA epitope mismatch), defined as absence of donor HLA class I alleles in the recipient, lead to NK alloreactivity in the graft versus host (GVH) direction resulting in protection against graft rejection, relapse, and graft-versus-host disease (GvHD).”
BackgroundModulation of NK cells with checkpoint inhibitors in the context of cancer immunotherapy
Sánchez-Correa, B., López-Sejas, N., Durán, E., Labella, F., Alonso, C., Solana, R., & Tarazona, R. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02336-6 · Cited by 61
Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy
Tarannum, M., Romee, R., & Shapiro, R. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.859177 · Cited by 63
“While the initial recognition of their anti-tumor efficacy came from studies of allogeneic stem cell transplantation, numerous other studies have demonstrated their cytotoxic potential against tumor targets even in non-transplant settings (3, 4).”
BackgroundIzard, C., Crocchiolo, R., Granjeaud, S., Kochbati, E., Just‐Landi, S., Chabannon, C., Frassati, C., Picard, C., Blaise, D., Olive, D., et al. (2015) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.11.681 · Cited by 67
Pluripotent stem cell-derived natural killer cells for cancer therapy
Knorr, D. A., & Kaufman, D. S. (2010) · Translational research · doi:10.1016/j.trsl.2010.07.008 · Cited by 64
“Here, they demonstrated NK cell-mediated allo-reactivity could eliminate relapse, graft rejection, and protect against graft-vs-host disease (GVHD) for patients with acute myelogenous leukemia (AML) [46].”
BackgroundInfluentialZhang, M., Davies, S. M., Camitta, B. M., Logan, B. R., Tiedemann, K., & Eapen, M. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2012.01.007 · Cited by 59
“Cytogenetic risk was defined as follows: low risk, hyperdiploid (chromosome number of 50 or higher), trisomies of 4, 10 and 17 and t (12; 21); high risk, hypodiploidy (chromosome number of 45 or less), translocation (9; 22); intermediate risk included all others abnormalities.”
BackgroundMethodRezvani, K., & Barrett, A. J. (2008) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2008.07.004 · Cited by 59
Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease
Davies, J. O. J., Stringaris, K., Barrett, A. J., & Rezvani, K. (2014) · Cytotherapy · doi:10.1016/j.jcyt.2014.03.009 · Cited by 65
“[40] showing that donor-versus-recipient NK cell alloreactivity could eliminate leukemia relapse without increasing the risk of graft-versus-host disease (GVHD) in HLAmismatched recipients resulted in a new era in the exploitation of NK cells for cancer immunotherapy.”
BackgroundAllogeneic stem cell transplantation for multiple myeloma: is there a future?
Dhakal, B., Vesole, D. H., & Hari, P. (2016) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.325 · Cited by 64
Nuebling, T., Schumacher, C. E., Hofmann, M., Hagelstein, I., Schmiedel, B. J., Maurer, S., Federmann, B., Rothfelder, K., Roerden, M., Dörfel, D., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0212 · Cited by 63
“2 M5 54 m 89 46, XY, del(9)(q13q22)[8]/48, XY[16] 109.”
InfluentialMin, B., Choi, H., Her, J. H., Jung, M. Y., Kim, H., Jung, M.-Y., Lee, E.-K., Cho, S., Hwang, Y. K., & Shin, E. (2018) · Immune Network · doi:10.4110/in.2018.18.e31 · Cited by 59
“Allogeneic NK cell therapy has been developed for the treatment of cancer patients because NK cells with KIR-major histocompatibility incompatibility could induce a graft-versus-tumor response without causing GVHD (21).”
BackgroundYang, Y.-M., Qin, Z., Du, D., Wu, Y., Qiu, S., Mu, F., Xu, K., & Chen, J. (2018) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-018-2069-y · Cited by 59
NK Cell Metabolism and TGFβ – Implications for Immunotherapy
Slattery, K., & Gardiner, C. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02915 · Cited by 70
“-host disease (93), and can positively promote a graft vs.”
BackgroundWoodard, P., Barfield, R. C., Hale, G. A., Horwitz, E. M., Leung, W. H., Ribeiro, R. C., Rubnitz, J. E., Srivastava, D. K., Tong, X., Yusuf, U., et al. (2005) · Pediatric Blood & Cancer · doi:10.1002/pbc.20596 · Cited by 59
Chronic GVHD as an autoimmune disease
Tyndall, A., & Dazzi, F. (2008) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2008.03.003 · Cited by 59
Acute graft versus host disease: pathophysiology, risk factors, and prevention strategies.
Ferrara, J. L. M., & Yanik, G. A. (2005) · PubMed · Cited by 59
Non-Myeloablative Transplantation
Maloney, D. G., Sandmaier, B. M., Mackinnon, S., & Shizuru, J. A. (2002) · Hematology · doi:10.1182/asheducation-2002.1.392 · Cited by 59
Baysal, H., Pauw, I. D., Zaryouh, H., Peeters, M., Vermorken, J. B., Lardon, F., Waele, J. D., & Wouters, A. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.737311 · Cited by 65
Natural killer cells and immune-checkpoint inhibitor therapy: Current knowledge and new challenges
Poggi, A. D., & Zocchi, M. R. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.11.016 · Cited by 65
“Also, donor NK cells can eliminate residual recipient T and dendritic cells, leading to a better engraftment and reduced GVHD.(130) In addition, it has been shown that KIRligand incompatibility can trigger anti-tumor cytotoxicity against melanoma and renal cell carcinoma: this killing is stronger than that exerted by…”
BackgroundInfluentialEngineered natural killer cells for cancer therapy
Biederstädt, A., & Rezvani, K. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.09.013 · Cited by 69
Zecher, D., Li, Q., Oberbarnscheidt, M. H., Demetris, A. J., Shlomchik, W. D., Rothstein, D. M., & Lakkis, F. G. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903729 · Cited by 58
Self-citationEvaluation of a Flow Cytometry‐Based Assay for Natural Killer Cell Activity in Clinical Settings
Valiathan, R., Lewis, J. E., Melillo, A. B., Leonard, S. M., Ali, K. H., & Asthana, D. (2011) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2011.02667.x · Cited by 58
Dendritic Cell Derived Cytokines in Human Natural Killer Cell Differentiation and Activation
Chijioke, O., & Münz, C. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2013.00365 · Cited by 60
“However, a completely different clinical benefit of DC interaction with NK cells was revealed when it was noticed that alloreactive NK cell therapy by haploidentical bone marrow transplantation against acute myeloid leukemia (AML) relapse also diminished graft-versus-host-disease (GvHD) (85, 86).”
BackgroundOhata, K., Espinoza, J. L., Lu, X., Kondo, Y., & Nakao, S. (2010) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2010.08.014 · Cited by 68
Terakura, S., Azuma, E., Murata, M., Kumamoto, T., Hirayama, M., Atsuta, Y., Kodera, Y., Yazaki, M., Naoe, T., & Kato, K. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2007.03.006 · Cited by 58
Navarro, A. G., Kmiecik, J., Leiss, L. W., Zelkowski, M., Engelsen, A. S. T., Bruserud, Ø., Zimmer, J., Enger, P. Ø., & Chekenya, M. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400859 · Cited by 58
“Allogeneic NK cells were demonstrated to mediate the graft-versus-leukemia effect through KIR-HLA class I ligand mismatch in patients receiving hematopoietic stem cell transplantation (HSCT) (18).”
BackgroundInfluentialKheav, V., Busson, M., Scieux, C., de Latour, R. P., Maki, G., Haas, P., Mazeron, M., Carmagnat, M., Masson, E., Xhaard, A., et al. (2014) · Haematologica · doi:10.3324/haematol.2014.108407 · Cited by 60
“NK cells are of major importance in allogeneic hematopoietic stem cell transplantation (HSCT) because of their ability to recognize and destroy abnormal leukocytes, such as leukemic cells.(2) They are the first subset of lymphocytes that reconstitute after allogeneic HSCT, with an early expansion of the cytokine-produ…”
BackgroundAggarwal, N., Swerdlow, S. H., Teneyck, S., Boyiadzis, M. M., & Felgar, R. E. (2015) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21349 · Cited by 62
“One patient with AML-NOS was found to have a t(9;22) but did not have a history of chronic myeloid leukemia.”
BackgroundTallerico, R., Garofalo, C., & Carbone, E. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00179 · Cited by 64
“There are clinical observations and ongoing clinical trials based on the idea that NK cells transferred from one individual to a non-MHC-I-matched patient can exert antileukemic effects based on “missing self ” recognition (5).”
BackgroundBoieri, M., Shah, P. N., Dressel, R., & Inngjerdingen, M. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00333 · Cited by 64
“The additional NK-cell mediated killing of host APC prevents activation of alloreactive T cells and, therefore, no aGvHD (189).”
BackgroundGenome-Wide CRISPR Screen Reveals Cancer Cell Resistance to NK Cells Induced by NK-Derived IFN-γ
Zhuang, X., Veltri, D., & Long, E. O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02879 · Cited by 65
Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease
Shrestha, B., Walton, K., Reff, J., Sagatys, E. M., Tu, N., Boucher, J. C., Li, G., Ghafoor, T., Felices, M., Miller, J. S., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci135754 · Cited by 58
NKG2D receptor–mediated NK cell function is regulated by inhibitory Ly49 receptors
Regunathan, J., Chen, Y., Wang, D., & Malarkannan, S. (2004) · Blood · doi:10.1182/blood-2004-03-1075 · Cited by 58
The immunobiology of natural killer cells and bone marrow allograft rejection
Barão, I., & Murphy, W. J. (2003) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2003.09.002 · Cited by 60
“[96], murine Ly49A /G2 /Ly49C/I and Ly49A /G2 /Ly49C/I NK-cell subsets obtained from splenocytes of H-2 mice were purified and assayed for alloreactivity by using H-2 or H-2 recipients as targets.”
BackgroundMethodSingle-cell analysis of the human NK cell response to missing self and its inhibition by HLA class I
Draghi, M., Yawata, N., Gleimer, M., Yawata, M., Valiante, N. M., & Parham, P. (2004) · Blood · doi:10.1182/blood-2004-08-3174 · Cited by 70
Murphy, W. J., Parham, P., & Miller, J. S. (2012) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.10.033 · Cited by 57
“published that KIR ligand mismatch between patients and their donors was associated with improved outcomes in myeloid leukemia after T-cell deplete haploidentical HCT(5).”
BackgroundMethodInfluential
Metadata
- Authors
- Ruggeri, L., Capanni, M., Urbani, E., Perruccio, K., Shlomchik, W. D., Tosti, A., Posati, S., Rogaia, D., Frassoni, F., Aversa, F., Martelli, M. F., & Velardi, A.
- Affiliations
- University of Perugia (IT)
- Yale University (US)
- Department of Clinical and Experimental Medicine, Section of Hematology and Clinical Immunology, Perugia University School of Medicine, Perugia, Italy.
- Ospedale Policlinico San Martino (IT)
- ORCID
- Venue
- Science
- Published
- 2002-03-15
- Volume
- 295
- Issue
- 5562
- Pages
- 2097-2100
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2147068163
- Cited by
- 3,380
- References
- 21
- Citations by year
- 2026: 46 · 2025: 92 · 2024: 112 · 2023: 134 · 2022: 157 · 2021: 156 · 2020: 139 · 2019: 155 · 2018: 140 · 2017: 157 · 2016: 152 · 2015: 171 · 2014: 134 · 2013: 162 · 2012: 150
- FWCI
- 63.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HL03979)
- Topics
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Life Sciences › Immunology and Microbiology › Immunology › Immune Cell Function and Interaction
- Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
- Keywords
- natural killer cells, NK cell alloreactivity, allogeneic hematopoietic stem cell transplantation, mismatched transplantation, graft-versus-host disease, graft rejection, leukemia relapse, T cell depletion, conditioning intensity, leukemia
- MeSH terms
- Acute Disease, Animals, Antigen-Presenting Cells, Graft Survival, Graft vs Host Disease, H-2 Antigens, Haplotypes, Histocompatibility Testing, Humans, Killer Cells, Natural, Leukemia, Myeloid, Mice, Inbred Strains, Receptors, Immunologic, Recurrence, T-Lymphocytes, Bone Marrow Transplantation, Mice, SCID, Mice, Inbred NOD, Hematopoietic Stem Cell Transplantation, Disease-Free Survival, Transplantation Conditioning, Graft vs Leukemia Effect, Mice, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Receptors, KIR
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.